Venetoclax Combination Regimens in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review
DOI:
https://doi.org/10.69639/arandu.v13i1.2284Palabras clave:
Leukemia, Myeloid, Acute, Antineoplastic Agents, Survival Rate, Remission InductionResumen
Purpose: This study evaluated the efficacy and safety of venetoclax combined with chemotherapy or hypomethylating agents in adult patients with relapsed or refractory acute myeloid leukemia who are ineligible for intensive chemotherapy. Methods: A systematic review of randomized and observational studies was conducted using MEDLINE, Embase, and the Cochrane Library through October 2024. Eligible studies included adult patients with relapsed or refractory acute myeloid leukemia treated with venetoclax-based combination regimens. Primary outcomes were overall survival, complete remission rates, and treatment-related adverse events. Results: Of 447 identified records, 12 studies met the inclusion criteria. Venetoclax combined with azacitidine showed improved overall survival and higher complete remission rates compared with decitabine-based regimens and was associated with fewer severe hematologic and infectious adverse events. Discussion: Venetoclax combined with azacitidine demonstrated superior efficacy and tolerability compared with decitabine-based regimens in relapsed or refractory acute myeloid leukemia. These findings support its use in patients ineligible for intensive chemotherapy, although further studies are needed to define responsive subgroups and long-term outcomes.
Descargas
Citas
1. Aldoss, I., Pullarkat, V., & Stein, A. S. (2021). Venetoclax-containing regimens in acute myeloid leukemia. Therapeutic Advances in Hematology, 12, 2040620720986646. https://doi.org/10.1177/2040620720986646
2. Bewersdorf, J. P., Giri, S., Wang, R., Williams, R. T., Tallman, M. S., Zeidan, A. M., et al. (2020). Venetoclax as monotherapy and in combination with hypomethylating agents or low-dose cytarabine in relapsed and treatment-refractory acute myeloid leukemia: A systematic review and meta-analysis. Haematologica, 105, 2659–2663. https://doi.org/10.3324/haematol.2020.256248
3. Burnett, A., & Stone, R. (2020). AML: New drugs but new challenges. Clinical Lymphoma, Myeloma & Leukemia, 20(6), 341–350. https://doi.org/10.1016/j.clml.2020.02.018
4. Che, Y., Tan, W., Liu, Y., Liu, H., Li, L., & Qin, F. (2024). Venetoclax in combination with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia. Tropical Journal of Pharmaceutical Research, 23, 209–214.
5. DiNardo, C. D., Maiti, A., Rausch, C. R., Pemmaraju, N., Naqvi, K., Daver, N. G., et al. (2020). 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy-ineligible and relapsed or refractory acute myeloid leukemia: A single-centre, phase 2 trial. The Lancet Haematology, 7, e724–e736. https://doi.org/10.1016/S2352-3026(20)30204-5
6. Du, Y., Li, C., Zhao, Z., Liu, Y., Zhang, C., & Yan, J. (2023). Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post-allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. BMC Cancer, 23, 764. https://doi.org/10.1186/s12885-023-11130-5
7. Gong, X., He, X., Wang, L., Yu, T., Liu, W., Xu, H., et al. (2024). Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: Latest updates from the 2023 ASH annual meeting. Experimental Hematology & Oncology, 13, 17.
8. Guerra, V. A., DiNardo, C., & Konopleva, M. (2019). Venetoclax-based therapies for acute myeloid leukemia. Best Practice & Research Clinical Haematology, 32, 145–153.
9. Hu, M., Li, W., Zhang, Y., Liang, C., Tan, J., & Wang, Y. (2023). Venetoclax in adult acute myeloid leukemia. Biomedicine & Pharmacotherapy, 168, 115820.
10. Lasica, M., & Anderson, M. A. (2021). Review of venetoclax in CLL, AML and multiple myeloma. Journal of Personalized Medicine, 11, 457. https://doi.org/10.3390/jpm11060457
11. MD Anderson Cancer Center. (n.d.). Venetoclax combination therapies found effective against challenging subtypes of acute myeloid leukemia. https://www.mdanderson.org/newsroom/venetoclax-combination-therapies-found-effective-against-challenging-subtypes-of-acute-myeloid-leukemia.h00-159466368.html
12. Shimony, S., Rozental, A., Bewersdorf, J. P., Goldberg, A. D., Stein, E. M., Grimshaw, A. A., et al. (2022). Investigational venetoclax combination therapy in acute myeloid leukemia: A systematic review and meta-analysis. Haematologica, 107, 2955–2960.
13. Tenold, M. E., Moskoff, B. N., Benjamin, D. J., Hoeg, R. T., Rosenberg, A. S., Abedi, M., et al. (2021). Outcomes of adults with relapsed/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center. Frontiers in Oncology, 11, 649209. https://doi.org/10.3389/fonc.2021.649209
14. Wang, H., Mao, L., Yang, M., Qian, P., Lu, H., Tong, H., et al. (2022). Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukemia: A multicenter, single-arm, phase 2 trial. The Lancet Haematology, 9, e415–e423.
15. Wang, W., Luo, Q., Chen, Q., Pang, A., & Fang, K. (2022). Analysis of the clinical efficacy of azacitidine plus venetoclax in the treatment of elderly patients with relapsed refractory acute myeloid leukemia. Evidence-Based Complementary and Alternative Medicine, 2022, 1–8.
16. Wei, M. Y., Yin, J., Liao, Y., Liu, J. Y., Zhao, Y., Chen, X. M., et al. (2024). The efficacy and safety of venetoclax combined with demethylating agents in elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences, 28, 1837–1846.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Carlos Camargo, Sebastián Villamizar Castellanos , Jenny Andrea Santisteban, Kevin Mosquera Restrepo , Gloria Ibis Tirado Romero
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
